A new tool for your pharma R&D strategy
In the past 10 years, investment in R&D by pharma has increased from $70 billion to over $150 billion. Yet getting a new drug to market is still risky. Fewer than 10% of candidates starting PHASE I clinical trials will make it through to regulatory approval, and for those that do, it will cost on average $1 billion.
Behind these figures lie crucial decisions about R&D strategy. How does each pharma company best use their resources to get the best return on investment in a competitive, rapidly changing healthcare market?
Create your own index
With ownership of the world’s leading R&D databases, Pharma Intelligence has created the definitive index of clinical and research excellence. Based on a series of key R&D indicators around portfolio strategy, business development, clinical trial operation and more, it allows you to create your own index by adjusting indicator weighting and comparing it to our experts’ analysis.
Try out the Clinical and Research Excellence Index
How does the index work? Watch our video below.